To understand the novel mechanism through which the MDM2-targeted therapy might be influencing tumor progression, we performed RNA seq on A549 (MDM2 amplified; p53 WT) and H1792 (MDM2 amplified; p53 mutant) cells treated with DMSO or RG7112 (MDM2 inhibitor). This evidence concerns the gene TP53 and neoplasm.